ClinicalTrials.gg
CompletedNCT05086445Updated Jul 16, 2026Results posted

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of LY3502970 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 5 sites in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
15th of 15
62 · median 546
Started
2021
with 1 other
Phase 1
2 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females not of
  • Have type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year
  • Have (HbA1c) value ≥ 7.0% and ≤ 10.0% for participants treated with diet and exercise or HbA1c ≥ 6.5% and ≤ 9.0% for participants who have washed out antidiabetic medications at screening
  • Have type 2 diabetes controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (OAM); either metformin, DPP-4 (dipeptidyl peptidase-4) inhibitor, or SGLT2 (sodium-glucose co-transporter-2) inhibitor within 3 months prior to screening. Participants must withdraw from their OAM treatment for at least 28 days prior to dosing.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus or latent diabetes in adults.
  • Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization
  • Have had an episode of severe hypoglycemia, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
  • Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of >500 milligram per deciliter (mg/dL).
  • Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases ( [ALT] and aspartate aminotransferase [AST]) greater than 3× (ULN).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    LY3502970 (Part A)

    Participants received single doses of LY3502970 administered orally.

    Drug: LY3502970

  • Experimental
    LY3502970 (Part B)

    Participants received multiple doses of LY3502970 administered orally.

    Drug: LY3502970

  • Placebo comparator
    Placebo (Part A)

    Participants received placebo administered orally.

    Drug: Placebo

  • Placebo comparator
    Placebo (Part B)

    Participants received placebo administered orally.

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline Through Follow-Up (Up To Week 15)

Secondary outcomes

  1. Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1

    PK: Cmax of LY3502970.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)

  2. Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

    PK: AUC\[0-tlast\] of LY3502970.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)

  3. Part B: PK: Cmax of LY3502970 on Day 84

    PK: Cmax of LY3502970.

    Time frame: Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)

  4. Part B: PK: AUC[0-tlast] of LY3502970 on Day 84

    PK: AUC\[0-tlast\] of LY3502970.

    Time frame: Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)

  5. Change From Baseline in Fasting Glucose

    Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.

    Time frame: Baseline through Day 85

  6. Change From Baseline in Glycated Hemoglobin (HbA1c)

    Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant is fitted as a random effect

    Time frame: Baseline through Day 85

  7. Change From Baseline in Body Weight

    Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\*Time + participant + Random Error, where participant was fitted as a random effect

    Time frame: Baseline through Day 88

07

Results

Posted Jul 16, 2026

Participant flow

A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.

Part A
Participant flow — Part A
MilestoneCohort 1a - PlaceboCohort 1a - LY3502970Cohort 2a - PlaceboCohort 2a - LY3502970Cohort 1b - Placebo QDCohort 1b - LY3502970 QDCohort 2b - Placebo QDCohort 2b - LY3502970 QDCohort 3a - Placebo QDCohort 3a - LY3502970 QDCohort 3b - Placebo QDCohort 3b - LY3502970 QD
Started2102900000000
Received at least one dose of study drug2102900000000
Completed282900000000
Not completed020000000000
Withdrew: Adverse event010000000000
Withdrew: Physician decision010000000000
Part B
Participant flow — Part B
MilestoneCohort 1a - PlaceboCohort 1a - LY3502970Cohort 2a - PlaceboCohort 2a - LY3502970Cohort 1b - Placebo QDCohort 1b - LY3502970 QDCohort 2b - Placebo QDCohort 2b - LY3502970 QDCohort 3a - Placebo QDCohort 3a - LY3502970 QDCohort 3b - Placebo QDCohort 3b - LY3502970 QD
Started2102917292727
Received at least one dose of study drug2102917292727
Completed192915282627
Not completed110002010100
Withdrew: Withdrawal by subject100002010000
Withdrew: Adverse event010000000100

Outcome measures

PrimaryNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Time frame:
Baseline Through Follow-Up (Up To Week 15)
Reported as:
Count of participants · Participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B2(or 3)/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B
TEAEs255411129
SAEs0000000
SecondaryPart A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1

PK: Cmax of LY3502970.

Time frame:
Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1
nanograms per milliliter (ng/mL)2 mg LY3502970 - Part A3 mg LY3502970 - Part A
Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 19.70 ± 3418.1 ± 38
SecondaryPart A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

PK: AUC\[0-tlast\] of LY3502970.

Time frame:
Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)
Reported as:
Geometric least squares mean · nanogram hour per milliliter (ng*h/mL)
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1
nanogram hour per milliliter (ng*h/mL)2 mg LY3502970 - Part A3 mg LY3502970 - Part A
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1236 ± 30412 ± 29
SecondaryPart B: PK: Cmax of LY3502970 on Day 84

PK: Cmax of LY3502970.

Time frame:
Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)
Reported as:
Geometric least squares mean · nanograms per milliliter (ng/mL)
Part B: PK: Cmax of LY3502970 on Day 84
nanograms per milliliter (ng/mL)12 mg LY3502970 - Part B24 mg LY3502970 - Part B45 mg LY3502970 - Part B
Part B: PK: Cmax of LY3502970 on Day 84112 ± 37139 ± 42279 ± 53
SecondaryPart B: PK: AUC[0-tlast] of LY3502970 on Day 84

PK: AUC\[0-tlast\] of LY3502970.

Time frame:
Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)
Reported as:
Geometric least squares mean · nanogram hour per milliliter (ng*h/mL)
Part B: PK: AUC[0-tlast] of LY3502970 on Day 84
nanogram hour per milliliter (ng*h/mL)12 mg LY3502970 - Part B24 mg LY3502970 - Part B45 mg LY3502970 - Part B
Part B: PK: AUC[0-tlast] of LY3502970 on Day 845860 ± 687480 ± 8311200 ± 80
SecondaryChange From Baseline in Fasting Glucose

Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.

Time frame:
Baseline through Day 85
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Glucose
milligrams per deciliter (mg/dL)Placebo QD - Part B2(or 3)/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B
Change From Baseline in Fasting Glucose7.40 (-4.08 to 18.89)-64.82 (-71.18 to -58.46)-61.08 (-67.12 to -55.03)-65.56 (-70.91 to -60.22)
Statistical analysis
  • Placebo QD - Part B vs 2(or 3)/3/6/12 mg LY3502970 QD - Part B · Ls mean difference: -72.22 · 90% CI -85.35 to -59.09
  • Placebo QD - Part B vs 2/3/6/8/12/24 mg LY3502970 QD - Part B · Ls mean difference: -68.48 · 90% CI -81.46 to -55.50
  • Placebo QD - Part B vs 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B · Ls mean difference: -72.97 · 90% CI -85.64 to -60.30
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1c)

Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant is fitted as a random effect

Time frame:
Baseline through Day 85
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Glycated Hemoglobin (HbA1c)
Percentage of HbA1cPlacebo QD - Part B2(or 3)/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B
Change From Baseline in Glycated Hemoglobin (HbA1c)0.67 (0.20 to 1.14)-2.16 (-2.45 to -1.87)-2.17 (-2.44 to -1.91)-2.28 (-2.52 to -2.04)
Statistical analysis
  • Placebo QD - Part B vs 2(or 3)/3/6/12 mg LY3502970 QD - Part B · Ls mean difference: -2.83 · 90% CI -3.38 to -2.28
  • Placebo QD - Part B vs 2/3/6/8/12/24 mg LY3502970 QD - Part B · Ls mean difference: -2.84 · 90% CI -3.38 to -2.30
  • Placebo QD - Part B vs 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B · Ls mean difference: -2.95 · 90% CI -3.48 to -2.42
SecondaryChange From Baseline in Body Weight

Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\*Time + participant + Random Error, where participant was fitted as a random effect

Time frame:
Baseline through Day 88
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Placebo QD - Part B2(or 3)/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B
Change From Baseline in Body Weight-0.5 (-2.3 to 1.3)-3.4 (-5.0 to -1.7)-6.9 (-8.4 to -5.4)-4.9 (-6.3 to -3.5)
Statistical analysis
  • Placebo QD - Part B vs 2(or 3)/3/6/12 mg LY3502970 QD - Part B · Ls mean difference: -2.9 · 90% CI -5.3 to -0.4
  • Placebo QD - Part B vs 2/3/6/8/12/24 mg LY3502970 QD - Part B · Ls mean difference: -6.4 · 90% CI -8.7 to -4.0
  • Placebo QD - Part B vs 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B · Ls mean difference: -4.3 · 90% CI -6.6 to -2.1

Adverse events

Collected over Baseline Through Follow-Up (Up To Week 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Part A0/4 (0%)0/4 (0%)2/4 (50%)
2 mg LY3502970 - Part A0/10 (0%)0/10 (0%)5/10 (50%)
3 mg LY3502970 - Part A0/9 (0%)0/9 (0%)6/9 (66.7%)
Placebo QD - Part B0/11 (0%)0/11 (0%)5/11 (45.5%)
2(or 3)/3/6/12 mg LY3502970 QD - Part B0/14 (0%)0/14 (0%)11/14 (78.6%)
2/3/6/8/12/24 mg LY3502970 QD - Part B0/17 (0%)0/17 (0%)13/17 (76.5%)
2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B0/18 (0%)0/18 (0%)9/18 (50%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlacebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B2(or 3)/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B
NauseaGastrointestinal disorders1/43/105/92/119/144/176/18
VomitingGastrointestinal disorders1/44/102/91/113/142/171/18
Decreased appetiteMetabolism and nutrition disorders0/41/100/91/115/143/173/18
ConstipationGastrointestinal disorders0/40/103/91/112/143/175/18
Abdominal discomfortGastrointestinal disorders1/41/100/90/111/143/170/18
HeadacheNervous system disorders1/40/101/91/113/140/172/18
Abdominal distensionGastrointestinal disorders0/42/100/90/111/141/170/18
DiarrhoeaGastrointestinal disorders0/40/100/92/111/142/170/18
EructationGastrointestinal disorders0/40/100/90/112/140/171/18
Head discomfortNervous system disorders0/40/100/90/112/140/170/18

Baseline characteristics

All participants who were enrolled in Part A, Part B. A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.

Age, Continuous
Age, Continuous(years)Placebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B3/6/12 mg LY3502970 QD - Part B2/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B3/6/12/24/36/45 mg LY3502970 QD - Part B2/3/6/12/24/36/45 mg LY3502970 QD - Part BTotal
Part A55.5 ± 1.753.1 ± 11.757.6 ± 5.5——————55.3 ± 8.5
Part B———57.7 ± 5.858.0 ± 6.856.3 ± 8.653.4 ± 10.057.6 ± 5.557.7 ± 7.156.1 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B3/6/12 mg LY3502970 QD - Part B2/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B3/6/12/24/36/45 mg LY3502970 QD - Part B2/3/6/12/24/36/45 mg LY3502970 QD - Part BTotal
Part A — Female0000000000
Part A — Male410900000023
Part B — Female0001100002
Part B — Male0001067179958
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B3/6/12 mg LY3502970 QD - Part B2/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B3/6/12/24/36/45 mg LY3502970 QD - Part B2/3/6/12/24/36/45 mg LY3502970 QD - Part BTotal
Part A — American Indian or Alaska Native0000000000
Part A — Asian410900000023
Part A — Native Hawaiian or Other Pacific Islander0000000000
Part A — Black or African American0000000000
Part A — White0000000000
Part A — More than one race0000000000
Part A — Unknown or Not Reported0000000000
Part B — American Indian or Alaska Native0000000000
Part B — Asian0001177179960
Part B — Native Hawaiian or Other Pacific Islander0000000000
Part B — Black or African American0000000000
Part B — White0000000000
Part B — More than one race0000000000
Part B — Unknown or Not Reported0000000000
Region of Enrollment
Region of Enrollment(Participants)Placebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B3/6/12 mg LY3502970 QD - Part B2/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B3/6/12/24/36/45 mg LY3502970 QD - Part B2/3/6/12/24/36/45 mg LY3502970 QD - Part BTotal
Japan410900000023
Region of Enrollment
Region of Enrollment(Participants)Placebo - Part A2 mg LY3502970 - Part A3 mg LY3502970 - Part APlacebo QD - Part B3/6/12 mg LY3502970 QD - Part B2/3/6/12 mg LY3502970 QD - Part B2/3/6/8/12/24 mg LY3502970 QD - Part B3/6/12/24/36/45 mg LY3502970 QD - Part B2/3/6/12/24/36/45 mg LY3502970 QD - Part BTotal
Japan0001177179960
08

Study locations

5 sites
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka, Osaka 532-0003, Japan
  • P-One Clinic
    Hachiōji, Tokyo 192-0071, Japan
  • Clinical Research Hospital Tokyo
    Shinjuku-ku, Tokyo 162-0053, Japan
  • Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic
    Toshima City, Tokyo 171-0014, Japan
  • Yokohama Minoru Clinic
    Yokohama, 232-0064, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2022, 9 months.

Results were first posted in Jul 2026, 3 years 10 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Oct 21, 2021
StartActual
Nov 12, 2021
Primary completionActual
Sep 5, 2022
CompletionActual
Sep 5, 2022
Results first posted
Jul 16, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05086445
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Nov 12, 2021
Primary completion
Sep 5, 2022
Completion
Sep 5, 2022
Results posted
Jul 16, 2026
Last update
Jul 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion